Journal of Clinical Medicine (May 2023)

Long-Term Safety and Efficacy of Pars Plana Vitrectomy for Uveitis: Experience of a Tertiary Referral Centre in the United Kingdom

  • Muhannd El Faouri,
  • Naseer Ally,
  • Myrta Lippera,
  • Siddharth Subramani,
  • George Moussa,
  • Tsveta Ivanova,
  • Niall Patton,
  • Felipe Dhawahir-Scala,
  • Carlos Rocha-de-Lossada,
  • Mariantonia Ferrara,
  • Assad Jalil

DOI
https://doi.org/10.3390/jcm12093252
Journal volume & issue
Vol. 12, no. 9
p. 3252

Abstract

Read online

Aim: To evaluate the effectiveness of pars plana vitrectomy (PPV) without macular intervention on uveitis eyes with persistent vitreous inflammation/opacities in terms of visual acuity (VA), intraocular inflammation and macular profile. Methods: We carried out a single-center retrospective study of patients with uveitic eyes that underwent PPV without intervention on the macula due to persistent vitreous inflammation/opacities. The primary outcome measures were best-corrected visual acuity (BCVA), intraocular inflammation and macular profile at 3, 12 and 24 months after surgery. Results: Twenty-seven eyes of twenty-six patients were analyzed. Overall, 77.8% had an improvement of VA (55% by 0.3 LogMAR or more); 62.5% of patients had no intraocular inflammation, and the number of patients on systemic steroids and second-line immunosuppressives was reduced by 26% at 12 months; 87.5% of patients had resolution of macular oedema at 12 months. Conclusion: PPV for persistent vitreous inflammation/opacities is safe and effective, showing beneficial outcomes in terms of improvement of BCVA and the reduction in inflammation.

Keywords